This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Technicians
- Nuria Ajenjo
- Daniel Alba
- Inmaculada Almenara
- María Jesús Artiga
- Francisco De Luna
- Cecilia Sobrino
The main goal of CNIO Biobank is to facilitate access to quality human samples and their associated data for research in cancer and related diseases, ensuring that both the acquisition and their use comply with all the legal and ethical principles that protect donors’ rights.
CNIO Biobank is a cross-service platform for CNIO researchers, and in general the wider scientific community, that offers extensive services covering all stages in research project management requiring the use of human samples. CNIO Biobank provides sample handling/processing; collection management; quality, ethical and legal advice; acquisition and design of valuable research collections; and negotiation with different stakeholders to find suitable samples and/or help obtain the ethical approval for any research project (involving human samples).
CNIO Biobank is authorised by the Consejería de Sanidad de la Comunidad Autónoma de Madrid (CAM) and registered in the Registro Nacional de Biobancos del Instituto de Salud Carlos III (ref. nº: B.000848).
Publications
- (2020). ACTN3 R577X Polymorphism Related to Sarcopenia and Physical Fitness in Active Older Women. Climacteric 30, 1-6. CNIO Publication.
- (2019). A Review of International Biobanks and Networks: Success Factors and Key Benchmarks-A 10-Year Retrospective Review.. Biopreservation & Biobanking 17, 512-519. CNIO Publication.
- (2019). In Search of an Evidence-Based Strategy for Quality Assessment of Human Tissue Samples: Report of the Tissue Biospecimen Research Working Group of the Spanish Biobank Network. J Transl Med 17, 370. CNIO Publication.
Open Access
- (2019). Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors. Eur J Med Chem 168, 87-109. CNIO Publication.
- (2018). In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer. Nat Commun 9, 3501. CNIO Publication.
Open Access